Takeda Pharmaceutical Co. Ltd

CIK: 0001395064

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (100.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

OVID

Ovid Therapeutics Inc.

10% Owner

HLVX

HilleVax, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (2 total)

OVID
Ovid Therapeutics Inc.
Dec 8, 2025
Conversion(C)
Indirect
1.3M shares-
HLVX
HilleVax, Inc.
Sep 17, 2025
Tender Offer(U)
Indirect
6.7M shares at avg. $1.95$13.1M

		Type	Shares	Price		Ownership
Dec 8, 2025	OVID Ovid Therapeutics Inc.	Conversion(C)	1,250,000	-	-	Indirect
Sep 17, 2025	HLVX HilleVax, Inc.	Tender Offer(U)	6,724,000	$1.95	$13,111,800	Indirect

1-2 of 2 transactions

About TAKEDA PHARMACEUTICAL CO LTD

TAKEDA PHARMACEUTICAL CO LTD (SEC CIK 0001395064) files insider reports with the SEC as 10% Owner of Ovid Therapeutics Inc. (OVID) and 10% Owner of HilleVax, Inc. (HLVX).

Signal8 holds 2 ownership filings by TAKEDA PHARMACEUTICAL CO LTD, all Form 4s, filed between Sep 19, 2025 and Dec 9, 2025. Those filings report 2 transactions, from Sep 17, 2025 to Dec 8, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on TAKEDA PHARMACEUTICAL CO LTD's filings is in CHUO-KU, TOKYO, M0.

Recent filings by TAKEDA PHARMACEUTICAL CO LTD

Dec 8, 2025: Conversion of OVID shares (Form 4, code C).
Sep 17, 2025: Tender of shares transaction of HLVX shares (Form 4, code U).

Other insiders filing for Ovid Therapeutics Inc. (OVID)

Carter Charles Ross, Chief Financial Officer
Greka Anna, Director
PAPADOPOULOS STELIOS, Director
Friedman Bart, Director
Fitzgerald Kevin Joseph, Director
LEVIN JEREMY M, Director

How to read Form 4 transaction codes